drugset / Trial / NCT05913232
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
RandomizedParallel-groupDouble-blindTreatment
Summary
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
Timeline
- Start
- 2023-08-28
- Primary completion
- 2024-08-29
- Completion
- 2024-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | H-1337 | Unknown | 0.6 % | Other |
| Subject | H-1337 | Unknown | 1 % | Other |
| Comparator | Timolol | Other / unclassified | 0.5 % | Other |